Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy

Journal of Clinical Pharmacology

Volumn 55, Issue 11, 2015, Pages 1229-1235

  Bisaso, Kuteesa R ^a,b   Mukonzo, Jackson K ^a,c   Ette, Ene I ^d  

^a MAKERERE UNIVERSITY   (Uganda)

^b Breakthrough Analytics Ltd   (Uganda)

^c Center for Operations Research in Africa   (Uganda)

^d Massachusetts   (United States)

Author keywords

efavirenz; Markov model; Monte Carlo simulation; neuropsychologic impairment; NONMEM

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABSORPTION LAG TIME; ABSORPTION RATE CONSTANT; ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NEUROPSYCHOLOGIC IMPAIRMENT; ORAL CLEARANCE; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; DOSE RESPONSE; HIV INFECTIONS; MARKOV CHAIN; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY SYNDROMES; PSYCHOLOGY;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; MALE; MARKOV CHAINS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84942983022     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.533     Document Type: Article

References (30)

1. Rao VR, Ruiz AP, Prasad VR., Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther. 2014; 11: 13.
2. Woods SP, Moore DJ, Weber E, Grant I,. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009; 19 (2): 152-168.
3. Cysique LA, Vaida F, Letendre S, et al., Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009; 73 (5): 342-348.
4. Cysique LA, Waters EK, Brew BJ., Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011; 11: 148.
5. Gutierrez F, Navarro A, Padilla S, et al., Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 41 (11): 1648-1653.
6. Fumaz CR, Munoz-Moreno JA, Molto J, et al., Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005; 38 (5): 560-565.
7. Blanch J, Martinez E, Rousaud A, et al., Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001; 27 (4): 336-343.
8. Mukonzo JK, Okwera A, Nakasujja N, et al., Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis. 2013; 13: 261.
9. Hinkin CH, Castellon SA, Durvasula RS, et al., Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002; 59 (12): 1944-1950.
10. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T., Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. J 2001; 15 (1): 71-75.
11. Shafran S, Lefebvre E, Baril J, Cornelson B, Walmsley S, Fong I,. Retrospective analysis of factors associated with discontinuation of EFV due to adverse effects. Paper presented at: 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires, Argentina.
12. Zaccarelli M SF, Liuzzi, G, et al., CNS side effects as main risk factor for EFV failure and transient HIV-RNA elevation. Paper presented at: 9th Conference of Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington.
13. Sadiq ST, Fredericks S, Khoo SH, Rice P, Holt DW,. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS. 2005; 19 (15): 1716-1717.
14. Ribaudo HJ, Haas DW, Tierney C, et al., Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006; 42 (3): 401-407.
15. Nyakutira C, Roshammar D, Chigutsa E, et al., High prevalence of the CYP2B6 516G->T(∗6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008; 64 (4): 357-365.
16. Mukonzo JK, Roshammar D, Waako P, et al., A novel polymorphism in ABCB1 gene, CYP2B6∗6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009; 68 (5): 690-699.
17. ENCORE1 Study Group, Puls R, Amin J, Losso M, et al., Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014; 383 (9927): 1474-1482.
18. Mukonzo JK, Owen JS, Ogwal-Okeng J, et al., Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One. 2014; 9 (1): e86919.
19. Goldenberg D, Boyle B., Psychiatric safety of efavirenz. Paper presented at 13th International AIDS Conference; July 9-14, 2000; Durban, South Africa.
20. Ette IE., Transition models in pharmacodynamics. In:, Ette IE, Williams JP, eds. Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons, Inc.; 2007.
21. Beal SL, Sheiner LB., The nonmem system. Amer Statist. 1980; 34: 118-119.
22. Boeckmann AJ, Sheiner LB, Beal SL., NONMEM Users Guides, NONMEM Project Group. San Francisco: University of California; 1994.
23. Lindbom L, Ribbing J, Jonsson EN., Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004; 75 (2): 85-94.
24. R: A Language and Environment for Statistical Computing [computer program]. Version 3.0.1. Vienna, Austria: R Foundation for Statistical Computing; 2013.
25. Jonsson EN, Karlson MO., Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58: 51-64.
26. Muenz LR, Rubinstein LV., Markov models for covariate dependence of binary sequences. Biometrics. 1985; 41 (1): 91-101.
27. Schoemaker RC, van Gerven JM, Cohen AF., Estimating potency for the Emax-model without attaining maximal effects. J Pharmacokinet Biopharm. 1998; 26 (5): 581-593.
28. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV., Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003; 43 (6): 610-623.
29. Siccardi M, Almond L, Schipani A, et al., Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin Pharmacol Ther. 2012; 92 (4): 494-502.
30. Clifford DB, Evans S, Yang Y, et al., Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005; 143 (10): 714-721.